PD-1 ELISA Kit

Catalog No. ABIN5026948

This Colorimetric ELISA kit is designed for the quantitative measurement of Human PD-1.

Quick Overview for PD-1 ELISA Kit (ABIN5026948)

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Reactivity: Human

Detection Method: Colorimetric

Method Type: Sandwich ELISA

Detection Range: 0.156-10 ng/mL

Application: ELISA

Sample Type: Plasma, Serum

Product Details PD-1 ELISA Kit

Minimum Detection Limit: 0.156 ng/mL

Purpose: This immunoassay kit allows for the in vitro quantitative determination of Human PDL1 concentrations in serum, plasma and other biological fluids. This kit is for Research use only. Not for use in diagnostic/therapeutics procedures.

Analytical Method: Quantitative

Sensitivity: < 0.094 ng/mL

Components: plate, standard, diluent, antibodies

Material not included: pipettes, tubes, reader, incubator

Application Details

Sample Volume: 100 μL

Assay Time: 3 - 4 h

Plate: Pre-coated

Protocol: This kit was based on sandwich enzyme-linked immune-sorbent assay technology. Anti- Human PD-1 antibody was pre-coated into 96-well plates. Biotin conjugated anti-human PD-1 detection antibody was used. Standards, test samples and biotin conjugated detection antibody were added to the wells subsequently. Wash buffer was used to wash any non-specific binding. HRP conjugated Streptavidin was used as secondary antibody. TMB substrates were used to visualize HRP enzymatic reaction. TMB was catalyzed by HRP to produce a blue color product that changed into yellow after adding acidic stop solution. The density of yellow is proportional to the Human PD-1 amount of samples captured in the plate. Optical Density (O.D) can be read at absorbance 450nm in a microplate reader. Concentration of Human PD-1 can be calculated using the standard curve.

Restrictions: For Research Use only

Handling

Precaution of Use: protect your eyes

Storage: 4 °C

Target Details for PD-1

Target: PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))

Alternative Name: PD-1 (Programmed Cell Death Protein1)

Pathways: Cancer Immune Checkpoints